Kenneth Michael Reali - 14 Mar 2022 Form 4/A - Amendment Insider Report for Bioventus Inc. (BVS)

Role
Fmr. CEO and Director, Director
Signature
/s/Anthony D'Adamio, Attorney-in-Fact
Issuer symbol
BVS
Transactions as of
14 Mar 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
21 Apr 2023, 17:19:31 UTC
Date Of Original Report
16 Mar 2023
Previous filing
10 Sep 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Stock Option (Right to Buy) Award $0 +466,054 $0.000000 466,054 14 Mar 2022 Class A Common Stock 466,054 $1.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options shall vest in four approximately equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

Remarks:

This Form 4 amendment is being filed to report the acquisition of stock options that were inadvertently omitted from the original filing.